Approved indications: Inlexzo is approved for adult patients with BCG‑unresponsive non‑muscle invasive bladder cancer (NMIBC) that includes carcinoma in situ (CIS), with or without associated papillary tumors, as a bladder‑preserving treatment option.

Off‑label or investigational uses: Inlexzo (also known as TAR‑200) is being studied in clinical trials for high‑risk NMIBC without CIS and for muscle‑invasive bladder cancer, but these uses are not FDA‑approved; outside of trials, off‑label use is uncommon and evidence is still limited.

Efficacy expectations: In the pivotal SunRISe‑1 study, about 82% of patients with BCG‑unresponsive CIS achieved a complete response (no visible tumor and negative urine tests), and roughly half of these complete responses lasted at least 12 months. Many patients see whether the treatment is working at the first formal assessment around 3 months, and treatment can continue for up to 14 cycles as long as the cancer remains controlled and side effects are acceptable. Compared with other bladder‑sparing options such as intravenous pembrolizumab or traditional intravesical chemotherapy, early data suggest higher complete‑response rates for Inlexzo, though there are no direct head‑to‑head trials and radical cystectomy remains the treatment with the most proven long‑term cancer control.

Typical dosing and how it is given: Inlexzo is supplied as a single‑dose 225 mg intravesical system that a trained healthcare provider inserts into the bladder through a urinary catheter in an outpatient setting; it remains in place for about 3 weeks, is then removed, and is re‑inserted every 3 weeks for up to 6 months (8 doses) and then every 12 weeks for up to 18 months (6 doses), or until recurrence, progression, or unacceptable toxicity.

What patients should do around each treatment:

• Do not empty your bladder immediately before insertion; having some urine present helps proper deployment.
• After insertion, you may urinate normally; you do not need to hold your urine.
• Drink roughly 6–7 cups (about 1.5 liters) of fluids per day during treatment unless your doctor gives different instructions, to maintain good urine flow for drug release.
• During the time the device is in place, avoid skin contact with urine: sit on the toilet to void, flush each time, and wash your hands and genital area with water after each urination; promptly wash any clothing soiled with urine separately.

Special dosing instructions:

• Inlexzo is for intravesical use only and must not be swallowed, injected, or given by any other route.
• Insertion and removal must always be done by a trained healthcare professional using the specific catheter and stylet supplied with the product, following the Instructions for Use.
• Your oncology/urology team will individualize how many cycles you receive based on how well the cancer responds and how well you tolerate treatment.

Missed dose guidance: If you miss an appointment for insertion or removal, contact your care team as soon as possible; the dose should be given or the device removed as close to the original schedule as can be safely arranged, and you should not attempt any adjustment yourself.

Overdose or device problems: Overdose is uncommon because dosing is controlled by the clinic, but if more than one device is suspected to be in place, if the device remains in the bladder beyond the planned 3‑week period, or if you develop severe symptoms (such as intense pelvic pain, high fever, or inability to urinate), seek urgent medical care so the team can locate and remove the device and treat any complications.

Common side effects (usually mild to moderate):

• Bladder and urinary symptoms are very common, including needing to urinate more often, urgency, pain or burning when urinating (dysuria), blood in the urine, bladder irritation, and pelvic or urinary tract pain.
• Urinary tract infections occur frequently and may require antibiotics; fever, chills, or worsening urinary symptoms should be reported promptly.
• Blood test changes can include mild anemia, low lymphocyte counts, and increases in kidney and liver lab values (creatinine, lipase, AST/ALT, potassium, etc.), which usually resolve with monitoring or dose timing adjustments.

Serious or rare adverse effects needing urgent medical attention:

• Signs of severe infection (high fever, chills, confusion, flank pain) or sepsis.
• Severe bladder pain, inability to urinate, or large amounts of blood or clots in the urine.
• Unusual confusion, severe fatigue, shortness of breath, or other sudden neurologic or systemic symptoms.
• Any suspected bladder perforation (sudden severe pelvic pain, difficulty passing urine, abdominal swelling) or traumatic catheterization.

Warnings and precautions:

• Bladder integrity: Inlexzo must not be used in patients with a known bladder perforation or significantly damaged bladder lining until this is fully healed, because systemic gemcitabine exposure and severe toxicity can occur.
• Risk with delaying cystectomy: In people with BCG‑unresponsive CIS, delaying bladder removal surgery can allow progression to muscle‑invasive or metastatic bladder cancer; a small but real proportion of patients on Inlexzo progressed to muscle‑invasive disease, so ongoing discussions about surgical options are important.
• Pregnancy and contraception: Gemcitabine can harm an unborn baby. Patients who can become pregnant should have a pregnancy test before starting, use effective contraception during treatment and for 6 months after final removal; males with partners who can become pregnant should use effective contraception during treatment and for 3 months after final removal.
• Breastfeeding: Breastfeeding is not recommended during Inlexzo treatment and for at least 1 week after the device is finally removed.
• Children and older adults: Safety and effectiveness have not been established in children; most studied patients were older adults (many ≥65 years), in whom the drug was generally tolerable with the urinary and laboratory side effects described.
• Kidney and liver disease: Because systemic levels are very low, no specific dose adjustments are defined for kidney or liver impairment, but people with significant organ dysfunction should be monitored closely and managed by an experienced oncology team.
• MRI safety: The device is MR‑Conditional and can be scanned safely only under specific MRI conditions; patients should carry their Inlexzo information card and inform imaging staff whenever an MRI is planned.

Overall safety profile: Compared with intravenous gemcitabine or other systemic cancer drugs, Inlexzo generally causes fewer whole‑body side effects because drug levels in the bloodstream are very low, but local bladder and urinary side effects and infections are common and sometimes serious.

Reporting side effects and safety updates: Patients and clinicians can report suspected adverse reactions to Janssen Biotech (1‑800‑526‑7736) or to the FDA MedWatch program (1‑800‑FDA‑1088 or the MedWatch website), where safety communications and updates are also posted.

Drug and supplement interactions:

• Because Inlexzo delivers gemcitabine mainly inside the bladder with very low blood levels, classic drug–drug interactions (for example through liver enzyme effects) are unlikely.
• Your doctor will still review all prescription medicines, over‑the‑counter drugs, and supplements, especially other chemotherapy agents or drugs that affect the bone marrow, kidneys, or liver, to avoid additive toxicity.
• Routine pain relievers, most antibiotics, and other common medicines are often compatible but should always be checked with your oncology or urology team.

Alcohol, food, and lifestyle:

• There are no specific food or alcohol restrictions unique to Inlexzo, but heavy alcohol use can worsen liver function and infection risk, so moderation is advised.
• Staying well hydrated is important during treatment; follow your care team’s fluid recommendations, especially if you have heart or kidney disease.

Imaging and procedures (including MRI):

• The Inlexzo device contains a metal wire and is classified as MR‑Conditional, meaning MRI scans are permitted only under defined scanner settings (1.5 or 3 Tesla and specific safety limits).
• Always tell radiology staff, emergency clinicians, and dentists that you have an Inlexzo device in your bladder and carry the device information card so they can check MRI or other imaging compatibility.
• Inform any doctor planning bladder procedures (such as cystoscopy or catheterization) that you are receiving Inlexzo so they can avoid dislodging or damaging the device.

Conditions and co‑medications requiring extra caution:

• Known or suspected bladder perforation or severe bladder wall injury (contraindication) — Inlexzo should not be used until the bladder is fully healed.
• History of severe allergic reaction to gemcitabine or to components of Inlexzo — the drug should not be given again.
• Significant immunosuppression or frequent infections — close monitoring is needed because urinary tract infections are common with Inlexzo.
• Severe kidney or liver disease — although systemic exposure is low, your team may monitor labs more closely and adjust other medications.
• Pregnancy or plans for pregnancy — Inlexzo can harm an unborn baby; effective contraception and pregnancy testing are required as directed by your care team.

Monitoring during therapy:

• Regular cystoscopy, urine cytology, and sometimes bladder biopsies are performed to check whether the cancer has responded or recurred.
• Periodic blood tests usually monitor blood counts, kidney function, and liver enzymes because lab abnormalities were observed in trials.
• Your doctor will also monitor for symptoms and signs of progression to muscle‑invasive disease, in which case surgery or other systemic treatments may be recommended.

Q: What is Inlexzo and what is it used for?
A: Inlexzo is a small device placed in the bladder that slowly releases the chemotherapy drug gemcitabine to treat adults with BCG‑unresponsive non‑muscle invasive bladder cancer that includes carcinoma in situ, with or without papillary tumors.

Q: How long does Inlexzo stay in my bladder and how often will I get it?
A: Each Inlexzo device stays in your bladder for about 3 weeks before your doctor removes it, and treatment is usually given every 3 weeks for up to 6 months and then every 12 weeks for up to 18 months, as long as it is working and side effects are manageable.

Q: What side effects should I watch for at home?
A: Expect more frequent urination, urgency, and burning, but call your care team right away if you develop fever, chills, worsening pain, trouble urinating, or a lot of blood or clots in your urine, as these can signal infection or other serious problems.

Q: Can I have an MRI while the Inlexzo device is in place?
A: In many cases you can have an MRI under specific conditions because the device is MR‑Conditional, but you must always tell the radiology staff you are on Inlexzo and show them your device card so they can confirm it is safe.

Q: Is Inlexzo safe during pregnancy or while breastfeeding?
A: Inlexzo can harm an unborn baby, so effective birth control is required during treatment and for several months afterward, and breastfeeding is not recommended during therapy or for 1 week after the final device is removed; discuss family‑planning goals with your oncology team before starting treatment.